ADDENDUM NUMBER TWO TO DEVELOPMENT AND LICENSING AGREEMENT FOR SAFETY "SELDINGER" NEEDLE DEVICEDevelopment and Licensing Agreement • January 3rd, 2005 • Med-Design Corp • Surgical & medical instruments & apparatus
THIRD AMENDMENT (“Amendment No. 3”)Development and Licensing Agreement • February 25th, 2014 • Gilead Sciences Inc • Biological products, (no disgnostic substances) • California
effective as of October 5, 2012 (“Amendment No. 3 Effective Date”) to the DEVELOPMENT AND LICENSING AGREEMENT dated as of September 27, 1996, as amended and supplemented by the FIRST AMENDMENT AND SUPPLEMENT effective as of November 15, 2005 and as amended by the SECOND AMENDMENT effective as of December 22, 2011 (the “Agreement”) by and between GILEAD SCIENCES, INC., a Delaware Corporation (“Gilead”), on the one hand, and F. HOFFMANN-LA ROCHE LTD, a corporation organized under the laws of Switzerland, and HOFFMANN-LA ROCHE INC., a corporation organized under the laws of New Jersey, on the other hand (collectively “Roche”). Capitalized terms used but not defined herein shall have the meanings assigned them in the Agreement.
EX-10.2 3 dex102.htm AMENDED AND RESTATED DEVELOPMENT AND LICENSING AGREEMENT CERTAIN INFORMATION IN THIS EXHIBIT IS SUBJECT TO A REQUEST FOR CONFIDENTIAL TREATMENT. IN ACCORDANCE WITH RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED,...Development and Licensing Agreement • May 5th, 2020 • New York
This Amended and Restated Development and Licensing Agreement (“Agreement”) is made and entered into as of the 25th day of February, 2004 (the “Effective Date”), between Tanox, Inc. (formerly known as Tanox Biosystems, Inc.), originally a Texas corporation and reincorporated as a Delaware corporation (“Tanox”), and Novartis Pharma AG, a company organized and existing under the laws of Switzerland (as successor-in-interest of Ciba-Geigy Limited) (“Novartis”). (Each of Novartis and Tanox is referred to herein individually as a “Party” and all are referred to collectively herein as the “Parties.”)
Software Development and Licensing AgreementDevelopment and Licensing Agreement • February 1st, 2022 • Nebraska
BETWEEN: The City of Lincoln, Nebraska, a municipal corporation, and Nebraska political Subdivision, and the County of Lancaster, Nebraska, a political subdivision (hereinafter the "City” shall include both entities)
AMENDMENT NO. 4 TO DEVELOPMENT AND LICENSING AGREEMENTDevelopment and Licensing Agreement • August 11th, 2015 • Eagle Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDMENT NO. 4 TO THE DEVELOPMENT AND LICENSING AGREEMENT (the “Amendment”) is made as of August 5, 2015 (the “Amendment Date”), by and between Eagle Pharmaceuticals, Inc. (“Eagle”), and SciDose LLC, (“SciDose”), and amends the June 12, 2007 Development and Licensing Agreement (the “Original Agreement”), by and between Eagle and SciDose. Capitalized terms used in this Amendment and not otherwise defined shall have the same meanings ascribed to such terms in the Original Agreement, as previously amended.
EXHIBIT ADevelopment and Licensing Agreement • March 3rd, 2006 • Gilead Sciences Inc • Biological products, (no disgnostic substances) • California
FIRST AMENDMENT AND SUPPLEMENT (“this Amendment”) dated as of November 15, 2005 to the DEVELOPMENT AND LICENSING AGREEMENT (“the Original Agreement” and, as amended and supplemented by this Amendment, “the Agreement”) dated as of September 27, 1996, by and between GILEAD SCIENCES, INC., a Delaware Corporation (“Gilead”), on the one hand, and F. HOFFMANN-LA ROCHE LTD, a corporation organized under the laws of Switzerland, and HOFFMANN-LA ROCHE INC., a corporation organized under the laws of New Jersey, on the other hand (collectively “Roche”). Capitalized terms used but not defined herein shall have the meanings assigned them in the Original Agreement.
Pursuant to 17 CFR 240.24-b, confidential information has been omitted in places marked “[***]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission...Development and Licensing Agreement • November 9th, 2009 • Terrestar Corp • Communications services, nec
This Amendment is entered into under the Master Development and Licensing Agreement (the “Agreement”) dated August 10 2007, as amended, between EB and TSN.
SECOND AMENDMENT (“Amendment No. 2”)Development and Licensing Agreement • February 23rd, 2012 • Gilead Sciences Inc • Biological products, (no disgnostic substances) • California
dated as of December 22, 2011 (“Amendment No. 2 Effective Date”) to the DEVELOPMENT AND LICENSING AGREEMENT dated as of September 27, 1996, as amended and supplemented by the FIRST AMENDMENT AND SUPPLEMENT effective as of November 15, 2005 (the “Agreement”) by and between GILEAD SCIENCES, INC., a Delaware Corporation (“Gilead”), on the one hand, and F. HOFFMANN-LA ROCHE LTD, a corporation organized under the laws of Switzerland, and HOFFMANN-LA ROCHE INC., a corporation organized under the laws of New Jersey, on the other hand (collectively “Roche”). Capitalized terms used but not defined herein shall have the meanings assigned them in the Agreement.
EXHIBIT 10.35 PRODUCT DISTRIBUTION, DEVELOPMENT AND LICENSING AGREEMENT AGREEMENT made as of the first day of May, 1999, between Aura Laboratories, Inc. ("Aura"), Andrx Pharmaceuticals, Inc. ("Pharmaceuticals") and Anda Generics, Inc. ("Anda"), each...Development and Licensing Agreement • August 16th, 1999 • Andrx Corp • Pharmaceutical preparations • Florida
AMENDMENT TO DEVELOPMENT AND LICENSING AGREEMENTDevelopment and Licensing Agreement • December 14th, 2022 • Eagle Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDMENT TO THE DEVELOPMENT AND LICENSING AGREEMENT (the “Amendment”) is made as of December 9, 2022 (the “Amendment Date”) and effective as of October 1, 2022, by and between Eagle Pharmaceuticals, Inc. (“Eagle”), and Robert One, LLC, (“Robert One”), and amends the February 13, 2009 Development and Licensing Agreement, by and between Eagle and Robert as amended on May 22, 2009, December 23, 2010, and August 5, 2015 (collectively the “Agreement”). Capitalized terms used in this Amendment and not otherwise defined shall have the same meanings ascribed to such terms in the Agreement.
CONFIDENTIAL PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. DEVELOPMENT AND LICENSING AGREEMENT This Development and License Agreement ("Agreement") is entered...Development and Licensing Agreement • April 14th, 2003 • Tower Semiconductor LTD • Semiconductors & related devices • California
AMENDMENT NO. 2 TO DEVELOPMENT AND LICENSING AGREEMENTDevelopment and Licensing Agreement • August 11th, 2015 • Eagle Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDMENT NO. 2 TO THE DEVELOPMENT AND LICENSING AGREEMENT (the “Amendment”) is made as of August 5, 2015 (the “Amendment Date”), by and between Eagle Pharmaceuticals, Inc. (“Eagle”), and Robert One, LLC, (“Robert”), and amends the February 13, 2009 Development and Licensing Agreement (the “Original Agreement”), by and between Eagle and Robert as amended on December 23, 2010. Capitalized terms used in this Amendment and not otherwise defined shall have the same meanings ascribed to such terms in the Original Agreement.
